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Abstract The rise in childhood obesity has lead to an
increased number of children with lipid abnormalities and
the predominance of a combined dyslipidemic pattern
characterized by a moderate-to-severe elevation in tri-
glycerides, normal-to-mild mild elevation in LDL choles-
terol and reduced HDL cholesterol. Although recently
published National Heart, Lung and Blood Institute
(NHLBI) guidelines represent a significant step forward in
managing primary dyslipidemias in pediatric patients, there
is still no general consensus regarding the pharmacologic
treatment of obesity-related lipid abnormalities in children.
The use of early pharmacologic intervention to control
dyslipidemias and reduce cardiovascular risk in young
children is only expected to increase given the steady
increase in obesity and emergence of atherosclerotic dis-
ease in pre-adolescents. Despite the increasing use of lipid-
lowering therapy in children over the last few years, diet
and lifestyle modification remain the first line therapy.
Given the challenges of instituting and maintaining life-
style modification in pediatric patients, however, it is likely
that institution of drug therapy may be required in many
children. Of all the medications currently available, the
fibric acid derivatives have a cholesterol lowering profile
that is most likely to be effective in obese children with the
high TG/low HDL phenotype and data from a recently
published study of gemfibrozil in children with metabolic
syndrome are promising. However, additional information
regarding the short and long-term safety and efficacy of
fibrate therapy in children with obesity-related lipid dis-
orders is needed before use of these agents can be
recommended.
1 Introduction
Coronary heart disease (CHD) is one of the leading causes
of mortality in the United States accounting for approxi-
mately 1 in 6 deaths each year [1]. Although the clinical
manifestations of CHD are most apparent in adults, there is
increasing evidence to suggest that the atherosclerotic
process begins during early childhood. Fatty streaks, the
earliest subclinical manifestations of atherosclerosis, have
been noted in the coronary arteries of children as young as
2 years of age and the prevalence in children ages 2 to
15 years is estimated to be 50 % [2]. The extent of ath-
erosclerotic lesions in children and young adults has also
been significantly correlated with traditional cardiovascular
risk factors (dyslipidemia, hypertension, obesity) and
increases with the number of factors present [2].
The number of children and adolescents with risk factors
for cardiovascular disease in the United States continues to
increase at an unprecedented rate in large part due to the
significant increase in childhood obesity. Over the past 3
decades, the prevalence of obesity in children ages 6 to
11 years has increased from 4 % to over 20 % [1]. Among
children ages 2 to 19 years, approximately 23.5 million
(32 %) are overweight and 12 million (17 %) are obese [1].
As in adults, there is a strong association between child-
hood obesity and the clustering of multiple cardiovascular
risk factors including insulin resistance, dyslipidemia and
elevated blood pressure, a combination known in adults as
the metabolic syndrome [3]. This clustering of obesity
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related risk factors continues into adult life and is strongly
associated with an accelerated atherosclerotic process.
Weight gain, insulin resistance and an atherogenic lipid pro-
file are also well-described side effects of psychotropic drugs
such as the second-generation antipsychotics now widely
used for a variety of conditions in pediatric patients [4].
With the increased prevalence of obesity in children,
secondary causes have superseded primary etiologies of
cardiovascular risk in pediatric patients. As a result of this
evolving phenotypic profile, the therapeutic targets and rec-
ommendations outlined in standard consensus guidelines for
the management of major cardiovascular risk factors in
children (which focus on risk factors of primary etiologies)
do not apply to a majority of at-risk children. This is partic-
ularly true for the management of pediatric dyslipidemias.
The increase in pediatric obesity rates has lead to the pre-
dominance of a combined dyslipidemic pattern in children
that is characterized by a moderate-to-severe elevation in
triglyceride (TG) level, normal-to-mild mild elevation in
LDL cholesterol and a reduced HDL cholesterol level [3].
When the original consensus guidelines were developed by
the National Cholesterol Education Program (NCEP) of the
National Heart, Lung and Blood Institute (NHLBI) in 1992,
however, the focus was almost exclusively on identification
and management of children with an elevated LDL choles-
terol level—a pattern most frequently associated with
dyslipidemias of primary or familial origin [5].
In late 2011, a set of integrated guidelines for cardiovas-
cular health and risk reduction in children and adolescents,
which includes updated recommendations for identifying and
managing dyslipidemias, was released by NHLBI and
endorsed by the American Academy of Pediatrics (AAP) [3].
The updated NHLBI guidelines, although reflective of the
changing dyslipidemia phenotype in children, do not provide
clear recommendations for management of children less than
10 years of age with concomitant risk factors (BMI C 95th
percentile, evidence of CHD) or complex mixed dyslipide-
mias that are associated with obesity. The guidelines also
highlight the lack of age-specific information regarding use
of cholesterol lowering therapies such as the fibrates, that
specifically target TG elevations commonly seen in obese
children. The use of early pharmacologic intervention to
control dyslipidemias and reduce cardiovascular risk in
young children is only expected to increase, however, given
the steady increase in obesity and emergence of atheroscle-
rotic disease in pre-adolescents.
2 Therapeutic Options for the Treatment of Secondary
Dyslipidemias in Children
There are several classes of medications available to treat
lipid abnormalities in pediatric patients. A majority of
children with secondary lipid abnormalities will have a
moderate-to-severe elevation in TG levels, normal-to-mild
mild elevation in LDL cholesterol and a reduced HDL
cholesterol level. Given that the individual phenotypic
profile will differ from patient to patient, however, fasting
lipid profile results should ultimately be used to guide
treatment selection.
2.1 HMG-CoA Reductase Inhibitors
The most common medications used to treat lipid abnor-
malities in children and adults are members of the HMG-
CoA reductase inhibitor, or statin class. Statins inhibit
3-hydroxy-3-methyl-glutaryl coenzyme, an endogenous
reductase involved in the rate-limiting step of cholesterol
synthesis. This action results in lower intracellular cho-
lesterol levels and up-regulation of LDL receptors leading
to increased clearance of LDL from the circulation. The
statins are very effective in reducing levels of LDL cho-
lesterol and have been reported to lower levels by 20–50 %
[6]. Adverse effects associated with statin use in adults
include increased hepatic transaminase levels, elevations in
creatine kinase, rhabdomyolysis (rare) and potential
teratogenicity.
HMG-CoA reductase inhibitors are the most studied
class of lipid lowering drugs in the pediatric population and
are the preferred pharmacologic therapy for lowering LDL
cholesterol in children and adolescents [3]. The extent of
LDL reduction achieved in children with statin therapy is
comparable to that observed in adults and ranges from 21
to 39 % depending on the dose and specific agent used [7].
Improvements in vascular endothelial function and carotid
artery intima media thickness (IMT), both markers of early
atherosclerosis, have also been observed in children ages 8
to 18 years after approximately 2 years of statin treatment
[8, 9]. Several longitudinal studies have also demonstrated
that, as a class, statins do not negatively impact growth,
development or sexual maturation when used in children
ages 8 to 18 years for an average duration of up to
4.5 years [10, 11]. However, there is still concern that
inhibition of cholesterol production during a critical period
of growth and maturation may have adverse consequences,
particularly in children that are pre-pubertal. Clinical
experience with the statins in children less than 8 years of
age therefore remains limited.
There are currently seven FDA-approved HMG-CoA
reductase inhibitors; six of the seven have a pediatric
indication for reducing LDL cholesterol in children with
familial hypercholesterolemia. Pravastatin (20 mg) is the
only statin indicated for use in children ages 8 years and
older; lovastatin, simvastatin, fluvastatin, atorvastatin,
pravastatin (40 mg) and rosuvastatin are approved for use
in children ages 10 years and older. It is important to note
336 M. J. Kennedy et al.
that labeling of statins for pediatric use was based solely
on demonstration of acceptable safety and efficacy in
children with familial and other monogenic forms of
hypercholesterolemia. Given the lack of comparable data
in children with secondary dyslipidemias, recommenda-
tions for the use of statins in this patient population have
been extrapolated from data in children with an entirely
different disease etiology. However, the dose-exposure-
response relationship for statins is likely different for
each dyslipidemic phenotype making the validity of
extrapolation between two disease etiologies somewhat
questionable.
2.2 Cholesterol Absorption Inhibitors
The cholesterol absorption inhibitors are a relatively new
class of medications that inhibit the uptake of dietary and
biliary cholesterol in the intestines most likely via blockade
of the Niemann-Pick C1-like 1 protein that mediates
intestinal cholesterol absorption. Reduced cholesterol
absorption results in decreased cholesterol delivery to the
liver. As a result, LDL receptor expression is upregulated
and LDL cholesterol clearance is increased. Given that
ezetimibe selectively inhibits cholesterol absorption, TG
and fat-soluble vitamin levels are not affected. The cho-
lesterol absorption inhibitors have been associated with
few adverse effects other than gastrointestinal discomfort
since they act locally in the gastrointestinal tract. However,
systemic effects are possible. Ezetimibe is the only medi-
cation in this class currently on the market and it is
available alone (Zetia) and in combination with the
HMG-CoA reductase inhibitor simvastatin (Vytorin).
Although ezetimibe effectively lowers LDL cholesterol
when used both alone and in combination with a statin in
adults, its clinical benefit on cardiovascular risk reduction
has yet to be proven [12].
The safety and efficacy of ezetimibe in children have
been evaluated in a limited number of short-term studies
[13–15]. When used as monotherapy for up to 16 months
in children as young as 5 years of age, ezetimibe effec-
tively lowers total cholesterol and LDL-cholesterol without
causing any significant side effects [13, 14]. In adolescents
with familial hypercholesterolemia (ages 10-17 years), co-
administration of ezetimibe with simvastatin for up to
53 weeks provides greater LDL cholesterol reduction
compared with simvastatin alone [15]. Ezetimibe is cur-
rently approved for the treatment of familial hypercholes-
terolemia in children 10 years of age and older. Given its
favorable adverse effect profile and availability as a small
tablet formulation, ezetimibe has the potential to become
an important new therapy for the treatment of elevated
LDL cholesterol in young children. It is likely that
ezetimibe will be used predominantly in children with
persistent elevations in LDL cholesterol after treatment
with other medications has failed. However, its precise role
in the treatment of primary and secondary dyslipidemias in
children remains undefined.
2.3 Fibric Acid Derivatives
Fibric acid derivatives (gemfibrozil, fenofibrate) are a
class of drugs traditionally used to treat hypertriglyceri-
demia in adults. The mechanism of action of this thera-
peutic class is complex and incompletely understood. It is
thought that fibric acid derivatives decrease hepatic pro-
duction of TG by increasing oxidation of fatty acids in
muscle and the liver and reducing the rate of hepatic
lipogenesis. These agents are also believed to increase
HDL cholesterol through a complex mechanism regulated
by the nuclear transcription activator, peroxisome prolif-
erator-activated receptor-a [16]. The fibric acid deriva-
tives primarily affect TGs (reduced levels) and HDL
cholesterol (increased levels). The effect on LDL cho-
lesterol is variable. In adults, the predominant side effects
are gastrointestinal upset and abdominal pain. Increased
liver function tests (LFTs) have also been reported.
Although uncommon, myopathy and rhabdomyolysis may
occur particularly when these agents are used in combi-
nation with a statin.
The fibric acid derivatives are useful in the treatment of
adult patients with combined dyslipidemias. Limited pub-
lished experience in children also suggests that these agents
may be effective in treating the obesity-related high
TG/low HDL cholesterol phenotype [17–20]. Use of fibric
acid derivatives for up to 6 months in children as young as
4 years of age has been shown to effectively lower total
cholesterol, LDL-cholesterol and TG levels and increase
HDL levels. Treatment was well tolerated although some
moderate increases in LFTs were noted [17–19]. The fibric
acid derivative, gemfibrozil, has also recently been shown
to effectively lower TG levels (54 % decrease) and
increase HDL cholesterol levels (17 % increase) in chil-
dren with metabolic syndrome when used in conjunction
with diet and exercise [20]. The drug was well tolerated
over the 8-month treatment period and only 2 of 47 chil-
dren reported muscle pain. At present, use of the fibric acid
derivatives is limited primarily to children with severe
elevations in TGs (C 500 mg/dL) who are at risk for
pancreatitis [3]. Although these agents currently do not
have FDA approved labeling for use in children, collective
experience from off-label use in young children suggests
that a reassessment of the role of fibric acid derivatives in
the treatment of obesity-related dyslipidemias may be
warranted.
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2.4 Bile Acid Binding Resins
Bile acid binding resins (cholestyramine, colestipol,
colesevelam), also known as bile acid sequestrants, act by
binding bile salts within the intestinal lumen and prevent-
ing their reuptake in the terminal ileum. This leads to a
depletion of bile salts and increased conversion of cho-
lesterol to bile in the liver. Decreased intracellular levels of
cholesterol in the hepatocytes also leads to upregulation of
LDL cholesterol receptor activity and increased clearance
of LDL from the circulation [21]. The bile acid binding
resins may increase TG levels and interfere with the
absorption of fat-soluble vitamins, particularly vitamins A,
D and K. They also have a high potential for drug inter-
actions since they act as an anion-absorbing resin in the
gut. These agents are not systemically absorbed but are
associated with significant gastrointestinal side effects
(including constipation, bloating and flatulence) that are
often treatment limiting.
Although never approved for use in children, bile acid
binding resins were long considered to be the only suitable
lipid lowering therapy in children and only recently have
been supplanted by statins as the preferred drug treatment
for increased LDL cholesterol in pediatric patients. Studies
of bile acid sequestrants in children and adolescents aged 6
to 18 years with elevated LDL cholesterol levels (131 to
190 mg/dL) have resulted in total cholesterol reductions of
7–17 % and LDL cholesterol reductions of 10–20 %
sometimes with a modest elevation in TG level [3]. As in
adults, adverse gastrointestinal effects are common in
children and compliance is frequently poor with both the
tablet and granular powder formulations with discontinu-
ation rates ranging from 20 to 30 % [22]. Recently, a
second generation bile acid binding resin with enhanced
binding capacity for bile acids (colesevelam), was shown to
effectively reduce LDL cholesterol alone and in combi-
nation with a statin in children with familial hypercholes-
terolemia with a relatively low incidence of gastrointestinal
side effects (10 %) and high compliance rate (over 85 %)
[23]. Further studies are needed however, to better delin-
eate the role of this novel bile acid binding resin in the
management of pediatric lipid disorders.
2.5 Niacin
Niacin is a hydrophilic B complex vitamin that reduces
LDL cholesterol and TG levels and increases HDL cho-
lesterol by decreasing the hepatic production and release of
very low-density lipoprotein (VLDL). It is also the only
medication known to reduce lipoprotein(a) levels. Niacin
has a very favorable lipid lowering profile, particularly for
patients with the high TG/low HDL phenotype, but its use
is limited by poor tolerance associated with its significant
adverse effects. The most common side effects of niacin
therapy are flushing, hepatic failure, myopathy, glucose
intolerance and hyperuricemia that can be severe and
treatment limiting.
To date, there has only one observational study per-
formed in children (n = 21, ages 4 to 14 years) treated
with niacin (500 to 2250 mg/day) [24]. In this study,
children received treatment for an average duration of
8 months and while statistically significant reductions in
total and LDL cholesterol were noted, there was no change
in TG or HDL cholesterol levels. The drug was also very
poorly tolerated with 71 % of children experiencing
flushing, 26 % experiencing elevation in hepatic transam-
inase concentrations and 38 % discontinuing therapy due
to adverse effects. Due to its poor tolerance, potential for
serious adverse effects and lack of safety and efficacy data
in pediatric patients niacin therapy is not routinely rec-
ommended for treatment of pediatric dyslipidemias and its
use is reserved for children with homozygous familial
hypercholesterolemia and/or elevated lipoprotein(a) levels.
2.6 x-3 Fatty Acids
The x-3 fatty acids, eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), have been studied exten-
sively for their ability to lower TG levels in adults. In
adults, x-3 fatty acids have been shown to lower TG levels
by 30–40 % and raise HDL cholesterol by 6 to 17 % when
administered in doses of 2 to 4 grams per day [3]. There is
also compelling evidence that x-3 fatty acids can reduce
the risk of coronary artery disease when used in conjunc-
tion with dietary modification [25]. Although their exact
mechanism of action remains unknown, the x-3 fatty acids
are thought to decrease hepatic fatty acid and TG synthesis
while simultaneously increasing fatty acid degradation and
oxidation leading to reduced VLDL cholesterol release [3].
In addition to their effects on TG, x-3 fatty acids also
increase HDL cholesterol and decrease LDL cholesterol
particle size.
x-3 fatty acids are not synthesized de novo in humans to
a great extent and fish is the major dietary source of EPA
and DHA. The American Heart Association (AHA) rec-
ommends that adults with coronary artery disease consume
about 1 gram of EPA ? DHA per day and that adults with
hypertriglyceridemia consume 2 to 4 grams of
EPA ? DHA per day [25]. The United States Government
has not established a recommended daily intake amount of
x-3 fatty acids in children although the typical pediatric
diet is generally deficient of x-3 fatty acids [26]. There are
many dietary supplements that contain EPA and DHA
currently on the market but these products are not regulated
by the FDA and are highly variable with respect to the
content of x-3 fatty acids and other ingredients. Lovaza,
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the only prescription form of x-3 fatty acids currently
available, is a highly concentrated formulation of the ethyl
esters of EPA and DHA and is approved as an adjunct to
dietary modification for the treatment of adults with
hypertriglyceridemia (TG C 500 mg/dL).
There have been no studies of Lovaza in pediatric
patients and experience with x-3 fatty acids in children is
limited to a small number of studies conducted with vari-
ous dietary supplement preparations. The EARLY study
was a 6-month, randomized double-blind, placebo-con-
trolled cross-over study conducted in 20 children in which
the effect of DHA on lipoprotein subclasses was evaluated
[27]. Although no significant quantitative changes in total
cholesterol, LDL cholesterol, HDL cholesterol or TG were
reported, there was a significant decrease in low-density
lipoprotein subclasses 1 and 3 and high density lipoprotein
2. Treatment with DHA supplementation was well toler-
ated and there were no reported adverse effects. In children
and adolescents (ages 11 to 21 years) with familial
hyperlipoproteinemia, a commercially available prepara-
tion of fish oil containing 18 % EPA, 12 % other x-3 fatty
acids and vitamin E also had no effect on lipid parameters
but was associated with epistaxis (8/11 subjects) and pro-
longations of bleeding time (3/11 subjects) [28].
While concerning, the majority of clinical evidence in
adults does not support an increased risk of bleeding with
high-dose fish oil even when used in combination with
anticoagulant or antiplatelet therapy [29]. It is important to
note, however, that because of developmental differences
in the dose-exposure-response relationship children may
have an increased predisposition to certain adverse effects
such as bleeding. Care must therefore be taken when
extrapolating clinical experience in adults to the pediatric
population. Given the positive effects on TG and HDL, x-3
fatty acids may be useful in the treatment of children with
the obesity-related dyslipidemic phenotype either alone or
in combination with niacin or a fibric acid derivative.
However, additional data are needed before definitive
recommendations regarding the use of x-3 fatty acids in
children can be made.
3 Overview of Updated NHLBI Expert Panel
Recommendations
3.1 Assessment of Lipid and Lipoprotein Levels
in Children and Adolescents
Preliminary evidence in children with familial hypercho-
lesterolemia suggests that early identification and control
of dyslipidemia substantially reduces accelerated early
atherosclerosis (as measured via carotid intima media
thickness) and future cardiovascular disease risk in
pediatric patients [8–11]. However, the age at which
screening for dyslipidemia should be initiated and the type
of screening approach (universal or targeted) remain
somewhat controversial. Multiple prospective screening
studies have mapped the normal distribution of lipids and
lipoproteins throughout childhood and have demonstrated a
clear developmental pattern characterized by a decrease in
total and LDL cholesterol (10–20 %) during puberty [3].
On the basis of this developmental pattern, the NHLBI
guidelines recommend universal screening in all children
between the ages of 9 and 11 years (Grade B recommen-
dation) [3]. Targeted screening is also recommended in
children ages 2 to 8 years in children with one or more of
the following conditions: diabetes, hypertension,
BMI C 95th percentile, a moderate to high risk medical
condition, positive history of smoking or family history
associated with increased cardiovascular risk (Grade B
recommendation) [3]. While this strategy will likely iden-
tify a majority of children with obesity-related dyslipide-
mias, it creates a clinical dilemma in that there are
currently no definitive recommendations for treating lipid
abnormalities in children less than 10 years of age.
The NHLBI guidelines delineate specific cut points for
acceptable, borderline-high and high plasma lipid, lipo-
protein and apolipoprotein concentrations in children and
adolescents and recommendations for initiation and modi-
fication of treatment are based on these cut points [3]. The
fasting lipid profile is the recommended method of
screening and decisions regarding the need for medication
therapy should be based on the average of results from at
least 2 profiles obtained at least 2 weeks but more than
3 months apart (Grade B recommendation). It is important
to note that most dyslipidemias associated with obesity do
not meet current cutoffs for pharmacologic treatment par-
ticularly with respect to LDL cholesterol levels. Given that
even moderate elevations in cholesterol are associated with
increased cardiovascular risk, however, it raises the ques-
tion as to whether current cut points are appropriate for
children with the obesity-related dyslipidemia phenotype.
3.2 Drug Therapy Selection for Children with the High
TG/Low HDL Lipid Phenotype
Non-pharmacologic approaches remain the cornerstone of
treatment for lipid abnormalities in children. The first step
proposed for managing children with elevated levels of
LDL cholesterol (C 130–250 mg/dL) or TG (C 100
mg/dL–500 mg/dL in children\10 years; C 130–500 mg/dL
in children 10–19 years) is a focused intervention on diet
and lifestyle modification for at least 3 to 6 months (Grade
A and B recommendation) [3]. In children with elevated
TG levels, reduction of simple carbohydrate intake and
weight loss can effectively reduce TGs. When associated
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with obesity, decreased caloric intake and increased
activity levels are also of primary importance. Unfortu-
nately, however, diet and lifestyle modification can be
difficult in practice and many times, social and family
circumstances can lead to relapses. This is particularly true
for children who are often not in control of their food
selections/choices.
The NHLBI guidelines recommend that children
younger than 10 years of age should not be treated with a
medication unless they have severe primary hyperlipidemia
or a high-risk condition that is associated with serious
medical morbidity (Grade C recommendation) [3].
Screening recommendations, however, suggest that fasting
lipid profiles be performed in children ages 2 to 8 years
with diabetes, hypertension, BMI C 95th percentile, a
moderate to high risk medical condition, positive history of
smoking or family history associated with increased car-
diovascular risk. It is therefore highly likely that children
who fall outside of the scope of the current treatment
recommendations but who have clinically significant lipid
abnormalities will be identified via this targeted screening
approach.
In children aged 10 to 21 years, the primary goal of
therapy is to control LDL cholesterol. In children with
normal LDL cholesterol who are less than 10 years of age
with TG levels between 100 and 200 mg/dL or between 10
to 19 years with TG levels between 130 and 200 mg/dL an
increase in dietary fish intake, in conjunction with contin-
ued diet and lifestyle modification, is recommended (Grade
D recommendation). If TG levels are between 200 and
499 mg/dL, then treatment with x-3 fatty acids may be
considered (Grade D recommendation). If non-HDL cho-
lesterol is also C 145 mg/dL then treatment with a statin,
fibrate and/or niacin can also be considered in consultation
with a lipid specialist (Grade D recommendation). Cur-
rently there are no specific recommendations for increasing
HDL cholesterol in this age group.
4 Challenges in the Pharmacotherapy of Children
with Secondary Hyperlipidemia
There are many challenges associated with the treatment of
lipid abnormalities in children and these challenges have
become even greater with the shift towards an obesity-
related dyslipidemia phenotype. While children with
familial hypercholesterolemia comprise the largest group
of pediatric patients with significantly elevated LDL cho-
lesterol, obese children with the high TG/low HDL phe-
notype currently comprise the majority of children with
lipid abnormalities. Most clinical experience in treating
lipid abnormalities in children, however, has been derived
from children with biochemical alterations in LDL
cholesterol and may not be applicable to children with
other forms of dyslipidemia. In adults, niacin and the fibric
acid derivatives are the most effective agents in lowering
TG and increasing HDL cholesterol levels. Of all the
cholesterol lowering therapies, these agents are the least
well tolerated, are associated with the highest rates of
treatment non-compliance and have the least experience in
pediatric patients.
While it may be possible to extrapolate information
regarding the efficacy of and/or response to cholesterol
lowering agents from adults to children, developmental
differences in drug absorption, distribution, metabolism,
and elimination make it difficult to develop pediatric dos-
ing recommendations using pharmacokinetic data gener-
ated in adults. This relative lack of age-specific information
regarding the dose-exposure response relationship for most
cholesterol lowering medications in young children and
adolescents makes dose selection and titration particularly
challenging. There is also limited information regarding
the safety of administering cholesterol lowering medica-
tions to pre-pubertal children and there is some concern
that exposure to these medications could potentially affect
cholesterol dependent production of steroid hormones in
the gonads and adrenal glands [30]. Although data from
short-term studies suggest that cholesterol-lowering ther-
apy does not adversely affect the processes of growth and
maturation, there have been no long-term studies evaluat-
ing the potential implications of exposure to these medi-
cations during critical periods of development. This has
resulted in a general reluctance to develop drug therapy
guidelines for children less than 10 years of age despite the
recommendation that children ages 2 to 8 years with risk
factors (including obesity) be screened for lipid
abnormalities.
Although attempts have been made to mathematically
model the best time to initiate lipid-lowering therapy the
optimal age at which treatment should be initiated remains
unknown [31]. Irrespective of when therapy is initiated,
however, it is likely that treatment with cholesterol-low-
ering medications will be life-long resulting in a cumula-
tive level of drug exposure that far exceeds that in adults.
Nevertheless, studies of lipid-lowering therapy in children
to date have all been relatively short term (less than
5 years) and the safety of long-term exposure to these
medications remains unknown. Because long-term follow-
up studies have not been completed, the impact of cho-
lesterol lowering therapy on reducing adverse cardiovas-
cular outcomes that often do not manifest until adulthood is
unclear. Carotid intima-media thickness may be a good
surrogate marker of treatment response in this patient
population although it may be years before the clinical
benefit of pharmacologic therapy can be documented using
this strategy. The ethics of prescribing life-long
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cholesterol-lowering therapy without a known risk-reduc-
tion benefit is therefore an important consideration. The
potential psychological effects of long-term cholesterol
lowering treatment, such as being embarrassed or stigma-
tized, is an additional unique pediatric consideration that
must also be recognized.
5 Summary and Conclusions
The dramatic rise in childhood obesity has led to an
increased number of children with lipid abnormalities that
are phenotypically different from those that were most
prevalent when the first comprehensive intervention
guidelines were published in 1992 [5]. The recently-pub-
lished NHLBI consensus guidelines, which recognize the
changing dyslipidemia phenotype and incorporate a deci-
sion tree for the pharmacologic management of increased
TG, represent a significant step forward in the management
of this continually evolving condition [3]. However, there
is still no general consensus regarding the pharmacologic
treatment of obesity-related lipid abnormalities that are
present in the vast majority of children. Studies to date
evaluating the safety and efficacy of lipid lowering therapy
in children with secondary hyperlipidemia have been lim-
ited and primarily focused on lowering LDL cholesterol.
Of all the medications currently available, the fibric acid
derivatives have a cholesterol lowering profile that is most
likely to be effective in obese children with the high TG/
low HDL phenotype and recently published data with
gemfibrozil in children with metabolic syndrome are
promising [20]. However, additional information regarding
the short and long-term safety and efficacy of fibrate
therapy in children with obesity-related lipid disorders is
needed.
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